当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い
。オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル と 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得
Xia Fang, Rongjuan Tang, Rongzhang Chen, Zhibing Luo, Xingya Xu, Shaoyong Gao, Ling Zheng
A Checkpoint Inhibitor-Based Immunotherapy (ICIs) has demonstrated outstanding efficacy in many solid tumors. However, some treated patients with positive expression of PD-L1 do not respond, and even develop hyper progression, and some patients with negative expression of PD-L1 can also benefit from immunotherapy combined with chemotherapy. There is growing need to identify biomarkers that will improve the selection of patients who will best respond to therapy. Intra-tumoral effective T cells are critical for anti-tumor effect, and some subpopulation of it have been verified as potential biomarkers for ICIs. In our previous study, a subset of intra-tumoral CD8+ T cells with stem-like properties has been identified as sensitive biomarker for predicting the response to and efficacy of PD-1/L1 blockade treatment with or without chemotherapy. In the current comment, the role and challenges of this cell subpopulation in anti-PD-1/L1 immunotherapy will be discussed.